<p>MaxCyte, Inc. (NASDAQ:MXCT - 获取免费报告) 的股价在周三交易中上涨了 0.7%。该公司股价最高达到 1.54 美元，最后交易价为 1.51 美元。在午盘交易中，约有 430,216 股成交，较平均每日成交量 627,622 股下降了 31%。该股票此前收盘价为 1.50 美元。</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>MXCT 已成为多份研究报告的主题。Weiss Ratings 在 12 月 29 日的报告中重申了对 MaxCyte 股票的 &#34;卖出 (e+)&#34; 评级。Wall Street Zen 在 11 月 22 日的研究报告中将 MaxCyte 股票的评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。两位股票研究分析师给予该股票买入评级，两位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;持有&#34;，共识目标价为 7.00 美元。</p>
<p><strong>查看我们关于 MaxCyte 的最新研究报告</strong></p>
<h2>MaxCyte 股价上涨 0.7%</h2>
<p>该公司 50 日移动平均线为 1.58 美元，200 日移动平均线为 1.69 美元。该股票的市值为 1.6107 亿美元，市盈率为-3.43，贝塔值为 1.22。</p>
<p>MaxCyte (NASDAQ:MXCT - 获取免费报告) 最近在 11 月 12 日发布了季度财报。该公司报告每股收益（EPS）为（0.12）美元，低于市场共识预期的（0.11）美元，差额为（0.01）美元。MaxCyte 的净利润率为负 132.57%，股本回报率为负 23.50%。该公司在本季度的收入为 641 万美元，而分析师预期为 837 万美元。整体来看，研究分析师预测 MaxCyte, Inc. 本年度将发布-0.42 的每股收益。</p>
<h2>对 MaxCyte 的对冲基金看法</h2>
<p>一些机构投资者最近增加或减少了对 MXCT 的持股。AQR Capital Management LLC 在第一季度将其在 MaxCyte 的持股增加了 227.3%。AQR Capital Management LLC 目前拥有 95,501 股该公司的股票，价值 261,000 美元，此前在上个季度增持了 66,323 股。Mudita Advisors LLP 在第一季度将其在 MaxCyte 的持股增加了 3.3%。Mudita Advisors LLP 目前拥有 3,328,441 股该公司的股票，价值 9,087,000 美元，此前在上个季度增持了 105,034 股。Strs Ohio 在第一季度购买了 MaxCyte 的新头寸，价值约 328,000 美元。Farther Finance Advisors LLC 在第二季度将其在 MaxCyte 的持股增加了 7,935.4%。Farther Finance Advisors LLC 目前拥有 11,812 股该公司的股票，价值 26,000 美元，此前在上个季度增持了 11,665 股。最后，CWM LLC 在第二季度将其在 MaxCyte 的持股增加了 92.7%。CWM LLC 目前拥有 12,132 股该公司的股票，价值 26,000 美元，此前在上个季度增持了 5,836 股。机构投资者和对冲基金持有该公司 68.81% 的股票。</p>
<h2>MaxCyte 公司简介</h2>
<p>(获取免费报告)</p>
<p>MaxCyte, Inc NASDAQ: MXCT 是一家临床阶段的细胞治疗平台公司，开发和商业化专有的流动电穿孔技术，以将大分子输送到活细胞中。该公司的仪器和耗材旨在支持细胞治疗的研究、临床前开发和临床规模生产，涵盖多种模式，包括工程化 T 细胞、自然杀伤 (NK) 细胞和诱导多能干细胞 (iPSC) 治疗。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票，胜过 MaxCyte</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>YDES 可能是 2026 年的生物科技突破</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 MaxCyte 吗？</h2>
<p>在你考虑 MaxCyte 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MaxCyte 并不在名单上。</p>
<p>虽然 MaxCyte 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MXCT

<p>MaxCyte（纳斯达克代码：MXCT）股价上涨 0.7%，至 1.51 美元，交易量较平均水平下降 31%。分析师的评级不一：两位买入，两位持有，一位卖出，市场共识目标价为 7.00 美元。该公司报告的季度每股收益为（0.12 美元），未达到预期，收入为 641 万美元。机构投资者持有该股票的 68.81%。MaxCyte 专注于细胞治疗技术，用于将大分子输送到活细胞中</p>

<p>MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report)'s share price was up 0.7% during trading on Wednesday . The company traded as high as $1.54 and last traded at $1.51. Approximately 430,216 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 627,622 shares. The stock had previously closed at $1.50.</p>
<div class="lb-trans"><p>MaxCyte, Inc. (NASDAQ:MXCT - 获取免费报告) 的股价在周三交易中上涨了 0.7%。该公司股价最高达到 1.54 美元，最后交易价为 1.51 美元。在午盘交易中，约有 430,216 股成交，较平均每日成交量 627,622 股下降了 31%。该股票此前收盘价为 1.50 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>MXCT has been the subject of a number of research reports. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of MaxCyte in a report on Monday, December 29th. Wall Street Zen upgraded shares of MaxCyte from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 22nd. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and a consensus price target of $7.00.</p>
<div class="lb-trans"><p>MXCT 已成为多份研究报告的主题。Weiss Ratings 在 12 月 29 日的报告中重申了对 MaxCyte 股票的 &#34;卖出 (e+)&#34; 评级。Wall Street Zen 在 11 月 22 日的研究报告中将 MaxCyte 股票的评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。两位股票研究分析师给予该股票买入评级，两位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;持有&#34;，共识目标价为 7.00 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on MaxCyte</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MaxCyte 的最新研究报告</strong></p>
</div><h2>MaxCyte Trading Up 0.7%</h2>
<div class="lb-trans"><h2>MaxCyte 股价上涨 0.7%</h2>
</div><p>The firm has a 50-day moving average of $1.58 and a 200 day moving average of $1.69. The stock has a market capitalization of $161.07 million, a price-to-earnings ratio of -3.43 and a beta of 1.22.</p>
<div class="lb-trans"><p>该公司 50 日移动平均线为 1.58 美元，200 日移动平均线为 1.69 美元。该股票的市值为 1.6107 亿美元，市盈率为-3.43，贝塔值为 1.22。</p>
</div><p>MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. The firm had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. As a group, research analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current year.</p>
<div class="lb-trans"><p>MaxCyte (NASDAQ:MXCT - 获取免费报告) 最近在 11 月 12 日发布了季度财报。该公司报告每股收益（EPS）为（0.12）美元，低于市场共识预期的（0.11）美元，差额为（0.01）美元。MaxCyte 的净利润率为负 132.57%，股本回报率为负 23.50%。该公司在本季度的收入为 641 万美元，而分析师预期为 837 万美元。整体来看，研究分析师预测 MaxCyte, Inc. 本年度将发布-0.42 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On MaxCyte</h2>
<div class="lb-trans"><h2>对 MaxCyte 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in MXCT. AQR Capital Management LLC grew its stake in shares of MaxCyte by 227.3% during the first quarter. AQR Capital Management LLC now owns 95,501 shares of the company's stock valued at $261,000 after acquiring an additional 66,323 shares in the last quarter. Mudita Advisors LLP boosted its holdings in MaxCyte by 3.3% in the first quarter. Mudita Advisors LLP now owns 3,328,441 shares of the company's stock valued at $9,087,000 after purchasing an additional 105,034 shares during the last quarter. Strs Ohio purchased a new position in MaxCyte in the first quarter valued at about $328,000. Farther Finance Advisors LLC grew its stake in MaxCyte by 7,935.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company's stock valued at $26,000 after purchasing an additional 11,665 shares in the last quarter. Finally, CWM LLC increased its holdings in MaxCyte by 92.7% during the 2nd quarter. CWM LLC now owns 12,132 shares of the company's stock worth $26,000 after purchasing an additional 5,836 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对 MXCT 的持股。AQR Capital Management LLC 在第一季度将其在 MaxCyte 的持股增加了 227.3%。AQR Capital Management LLC 目前拥有 95,501 股该公司的股票，价值 261,000 美元，此前在上个季度增持了 66,323 股。Mudita Advisors LLP 在第一季度将其在 MaxCyte 的持股增加了 3.3%。Mudita Advisors LLP 目前拥有 3,328,441 股该公司的股票，价值 9,087,000 美元，此前在上个季度增持了 105,034 股。Strs Ohio 在第一季度购买了 MaxCyte 的新头寸，价值约 328,000 美元。Farther Finance Advisors LLC 在第二季度将其在 MaxCyte 的持股增加了 7,935.4%。Farther Finance Advisors LLC 目前拥有 11,812 股该公司的股票，价值 26,000 美元，此前在上个季度增持了 11,665 股。最后，CWM LLC 在第二季度将其在 MaxCyte 的持股增加了 92.7%。CWM LLC 目前拥有 12,132 股该公司的股票，价值 26,000 美元，此前在上个季度增持了 5,836 股。机构投资者和对冲基金持有该公司 68.81% 的股票。</p>
</div><h2>MaxCyte Company Profile</h2>
<div class="lb-trans"><h2>MaxCyte 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>MaxCyte, Inc NASDAQ: MXCT is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company's instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.</p>
<div class="lb-trans"><p>MaxCyte, Inc NASDAQ: MXCT 是一家临床阶段的细胞治疗平台公司，开发和商业化专有的流动电穿孔技术，以将大分子输送到活细胞中。该公司的仪器和耗材旨在支持细胞治疗的研究、临床前开发和临床规模生产，涵盖多种模式，包括工程化 T 细胞、自然杀伤 (NK) 细胞和诱导多能干细胞 (iPSC) 治疗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than MaxCyte</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>A month before the crash</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 MaxCyte</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>YDES 可能是 2026 年的生物科技突破</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MaxCyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 MaxCyte 吗？</h2>
</div><p>Before you consider MaxCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 MaxCyte 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MaxCyte 并不在名单上。</p>
</div><p>While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MaxCyte 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MaxCyte（NASDAQ:MXCT）股价上涨 0.7% - 现在是买入的好时机吗？